Debanjan Ray, Chief Financial Officer at CytomX Therapeutics, Inc. (CTMX), sold 53,000 shares at $29.40 ($1.6M) on 2018-03-01, disclosed to the SEC on 2018-03-05.
Open-market sale of $1.6M CTMX by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $29.40 | 13,000 | $382K | 23.9% |
| 2 | $30.06 | 5,515 | $166K | 10.4% |
| 3 | $30.06 | 5,515 | $166K | 10.4% |
| 4 | $30.41 | 12,541 | $381K | 23.9% |
| 5 | $30.41 | 12,541 | $381K | 23.9% |
| 6 | $31.02 | 1,944 |
| $60K |
| 3.8% |
| 7 | $31.02 | 1,944 | $60K | 3.8% |
| Total | $30.13 avg | 53,000 | $1.6M | 100% |
| Filing → |
| CTMX | SELL | 2018-10-02 | $55K | — | Filing → |
| CTMX | SELL | 2018-09-06 | $67K | — | Filing → |
| CTMX | SELL | 2018-08-02 | $78K | — | Filing → |